The consumer welfare implications of governmental policies and firm strategy in markets for medicines

Chirantan Chatterjee, Kensuke Kubo, Viswanath Pingali

研究成果: Article

13 引用 (Scopus)

抜粋

This paper empirically examines the consumer welfare implications of changes in government policies related to patent protection and compulsory licensing in the Indian market for oral anti-diabetic (OAD) medicines. In contrast to previous studies on the impact of pharmaceutical patents in India, we observe, and estimate the welfare effects accruing from differential pricing and voluntary licensing strategies of patent-holding innovator firms. Three novel molecules belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of OADs have been launched in India by the patent holders, at lower prices than those prevailing in the developed countries. Using aggregate market transaction data, we structurally estimate demand and supply and use the parameter estimates in our model to simulate consumer welfare under various counterfactual scenarios. Our results suggest that the introduction of DPP-4 inhibitors generated a consumer surplus gain of around 7.6 cents per day for a typical DPP-4 inhibitor user under the existing differential pricing and voluntary licensing strategies. If the innovators decide to price at developed-country levels, this surplus is eliminated almost entirely. The issuance of compulsory licensing does not always improve consumer welfare because if innovators defer or delay the introduction of new drugs in response, the loss in consumer welfare could be substantial.

元の言語English
ページ(範囲)255-273
ページ数19
ジャーナルJournal of Health Economics
44
DOI
出版物ステータスPublished - 2015 12 1
外部発表Yes

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

フィンガープリント The consumer welfare implications of governmental policies and firm strategy in markets for medicines' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用